Health Care·Life Sciences Tools & Services·$7.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.64 | N/A | +17.14% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.64 | N/A | +17.14% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook on specific product lines while acknowledging broader market pressures. They did not provide detailed guidance for the upcoming quarters.
Management highlighted strong performance in key product areas.
They expressed confidence in long-term growth despite current market challenges.
Bio Rad Laboratories reported better-than-expected earnings per share, which indicates strong performance in certain areas. However, the stock fell by 2.05% following the report, likely due to the lack of revenue data and guidance. Investors may be cautious as the company navigates market challenges without clear future projections.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WILLIS TOWERS WATSON
Aug 6, 2018